SCHEMBL693383

SCHEMBL693383

O=C(O)COc1cccc2c(CCC(=O)NC(c3ccccc3)c3ccccc3)cccc12

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
MAPT P10636 1/20 0.47
TSHR P16473 1/20 0.45
PTGIR P43119 9/20 0.43
TBXA2R P21731 6/20 0.43
SLC6A9 P48067 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8202557 0.92 SLC6A9 (0.48) TDP1KDM4EALDH1A1HPGDMAPT
SCHEMBL8202190 0.91 MAPK1 (0.43) TDP1KDM4EALDH1A1HPGDMAPT
SCHEMBL8206250 0.91 MAPT (0.47) TDP1KDM4EALDH1A1HPGDMAPT
SCHEMBL8202181 0.90 TSHR (0.48) TDP1KDM4EMAPTTSHRMEN1
SCHEMBL8418748 0.89 KMT2A (0.53) TDP1KDM4EALDH1A1HPGDMAPT
SCHEMBL8417285 0.89 KMT2A (0.53) TDP1KDM4EALDH1A1HPGDMAPT
SCHEMBL8420212 0.88 ALDH1A1 (0.51) TDP1KDM4EALDH1A1HPGDMAPT
SCHEMBL8201828 0.87 MAPT (0.43) TDP1KDM4EALDH1A1HPGDMAPT
SCHEMBL8206771 0.87 MAPT (0.42) TDP1MAPTTSHRSLC6A9SLC6A5
SCHEMBL8420341 0.86 ALDH1A1 (0.57) TDP1KDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270489-A1 Remedy for Cartilage-Related Diseases ONO PHARMACEUTICAL CO., LTD. 2007-11-22 US claimed
EP-1661580-A1 REMEDY FOR CARTILAGE-RELATED DISEASES ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP claimed
EP-0719760-B1 Naphthalene derivatives and their use as PGE2 agonists and antagonists ONO PHARMACEUTICAL CO (JP) 1999-09-22 EP claimed
EP-0719760-A1 Naphthyloxyacetic acid derivatives and their use as PGW2 agonists and antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 1996-07-03 EP claimed
JP-8239356-A None JP disclosed
US-20120316241-A1 REMEDY FOR CARTILAGE-RELATED DISEASES ONO PHARMACEUTICAL CO., LTD. (JP) 2012-12-13 US disclosed
EP-2422814-A1 Remedy for cartilage-related diseases Ono Pharmaceutical Co., Ltd. (JP) 2012-02-29 EP disclosed
US-20070270489-A1 Remedy for Cartilage-Related Diseases ONO PHARMACEUTICAL CO., LTD. 2007-11-22 US disclosed
US-20060128810-A1 Remedies for allergic diseases KYOTO UNIVERSITY (JP) 2006-06-15 US disclosed
EP-1661580-A1 REMEDY FOR CARTILAGE-RELATED DISEASES ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed
EP-1563845-A1 REMEDIES FOR ALLERGIC DISEASES ONO PHARMACEUTICAL CO., LTD. (JP) 2005-08-17 EP disclosed
US-6013673-A ADMINISTERING AN EFFECTIVE AMOUNT OF A NAPHTHYLOXYACETIC ACID DERIVATIVE OR NONTOXIC ACID ADDITION SALT OR HYDRATE TO TREAT OR PREVENT ABORTION, PAINE, DIARRHEA, CATHARTICS, ULCER, GASTRITIS, HYPERTENSION AND THROMBOSIS ONO PHARMACEUTICAL CO., LTD. (JP) 2000-01-11 US disclosed
EP-0719760-B1 Naphthalene derivatives and their use as PGE2 agonists and antagonists ONO PHARMACEUTICAL CO (JP) 1999-09-22 EP disclosed
JP-H08239356-A NAPHTHYLOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT ONO PHARMACEUT CO LTD 1996-09-17 JP disclosed
EP-0719760-A1 Naphthyloxyacetic acid derivatives and their use as PGW2 agonists and antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 1996-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270489-A1 Remedy for Cartilage-Related Diseases COL2A1, PTGES3, PTGER3 TDP1 4790/4885KDM4E 4036/4885ALDH1A1 1684/4885
US-20120316241-A1 REMEDY FOR CARTILAGE-RELATED DISEASES COL2A1, PTGES3, PTGER3 TDP1 4790/4885KDM4E 4036/4885ALDH1A1 1684/4885
US-20060128810-A1 Remedies for allergic diseases PTGER3, PTGER1, PTGES3 TDP1 4838/4885KDM4E 3806/4885ALDH1A1 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.